MarketBeat on MSN
Akebia Therapeutics Q2 earnings call highlights
Akebia Therapeutics Surges on FDA Approval for Anemia Treatment Akebia Therapeutics (NASDAQ:AKBA) reported second-quarter ...
We issued an updated research report on Keryx Biopharmaceuticals, Inc. KERX on Sep 26, 2017. Notably, the company's only marketed product, Auryxia (ferric citrate) is approved in the United States for ...
Keryx’s Auryxia has so far struggled to get off the ground. But after winning its second FDA approval, the company’s now prepping for a launch that it thinks can take the drug to the next level.
Hosted on MSN
Akebia outlines phase II FSGS study of up to ~60 patients as Vafseo reaches nearly 7,500 patients
"We are very pleased and excited by the start to 2026" (CEO, President & Director John Butler), highlighting three execution priorities: "drive the near-term launch performance of Vafseo," "continue ...
Keryx Biopharmaceuticals Inc.'s KERX shares rallied 3.8% on the company's announcement of additional data from a phase III study on Auryxia for the treatment of iron deficiency anemia (IDA) in ...
Keryx Announces Two National Insurance Providers Added Auryxia™ to Their Medicare Part D Formularies
BOSTON, MA, June 24, 2015 – Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease, today announced ...
In September 2018, the Centers for Medicare & Medicaid Services (CMS) sent an email announcing that it would no longer cover Auryxia®. Auryxia® is an FDA approved medicine that treats iron deficiency ...
(RTTNews) - Akebia Therapeutics, Inc. (AKBA) Thursday announced positive results from its Phase 4 collaborative study, IMPACT, which examined the effects of Auryxia or ferric citrate as the primary ...
Please provide your email address to receive an email when new articles are posted on . The U.S. Food and Drug Administration has accepted for review the supplemental New Drug Application for Keryx ...
Akebia Therapeutics (NASDAQ:AKBA) stock fell ~22% on Thursday despite Q4 results beating estimates. Net loss narrowed to -$7.55M, compared to -$70.68M in Q4 2021. Total revenue declined -7.4% Y/Y to ...
DUBLIN--(BUSINESS WIRE)--The "Drug Analysis: Auryxia" drug pipelines has been added to ResearchAndMarkets.com's offering. Auryxia (ferric citrate; Keryx Biopharmaceuticals/Japan Tobacco/Torii ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results